In this study, we found that both the oral solution and solid dispersion are applicable to enhance drug solubility for human ADME studies and that the solid dispersion is better than the oral solution for preparing the to-be-marketed formulation. We hope that the findings of this study will advance the development of S-892216 and contribute to improving the quality of life for patients suffering from COVID-19 around the world.